Connection

Kathrin Jansen to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Kathrin Jansen has written about Antibodies, Neutralizing.
Kathrin Jansen
Connection Strength
0.214
Antibodies, Neutralizing
  1. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
    View in: PubMed
    Score: 0.033
  2. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
    View in: PubMed
    Score: 0.033
  3. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
    View in: PubMed
    Score: 0.033
  4. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
    View in: PubMed
    Score: 0.033
  5. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
    View in: PubMed
    Score: 0.033
  6. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
    View in: PubMed
    Score: 0.032
  7. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
    View in: PubMed
    Score: 0.008
  8. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.